

A PhD outside Belgium

Valérie Smolders

Marie Curie PhD Research Fellow

Department of Biology and Biotechnology, University of Barcelona, Spain

Email: valerie.smolders@ub.edu




The project leading to this application has received funding from the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 675527

Introductie



Studie Traject




- Bachelor Farmaceutische Wetenschappen (2013)
- Master in Geneesmiddelen Ontwikkeling: apotheker (2015)



- Thesis in Medicinale chemie:

RIP Kinasen en necroptotische pathways in de cellulaire fysiologie: nieuwe remmers en hun inhibitiespectrum binnen de kinase familie

- Engelse studie (2015)
 - C2 certificaat in Engels



PhD positie in Barcelona

- 3 jarig doctoraat

- Hoofdactiviteit: Hospital Clinic – IDIBAPS*
- *Secondment* in Nederland
- Industriële *secondment* in België

- Doctoraatsprogramma:

Biologie en Biotechnologie



* IDIBAPS: Institut d'Investigacions Biomèdiques August Pi i Sunyer

Hoe beginnen?

- Praten met collega's en professionals
- Internet: vacatures online
 - Universiteit Antwerpen > JOBS > VACATURES (België)
 - EURAXESS – Researchers in Motion (Europees)
 - AcademicPositions.eu (Europees)



Solliciteren voor een project

- Wees realistisch
- Lees aandachtig de vacature
 - Aarzel niet om extra informatie te vragen
 - Doe opzoekwerk (instituut, onderzoeksvelden, artikels, ...)
- Neem de tijd om je aanvraag te personaliseren voor elk project (motivatie, ervaring, ...)

Mijn project: H2020-MSCA-ITN (1)



(Horizon2020 – Marie Skłodowska-Curie Actions – Innovative Training Networks)

1. Eerste selectieronde:

- *Open call worldwide* (competitief)
- Gedetailleerd CV
- Uitgebreid projectvoorstel
- *Research statement*
- Motivatie
- Aanbevelingsbrief
 - Ervaring/ summer schools/ ...

Mijn project: H2020-MSCA-ITN (2)



(Horizon2020 – Marie Skłodowska-Curie Actions – Innovative Training Networks)

2. Tweede selectieronde: sollicitaties

- Via skype
 - Engels
 - Meerdere personen
 - Ruimte
 - Internet verbinding
 - Notificaties
- Wees voorbereid

Mijn project: H2020-MSCA-ITN (3)

(Horizon2020 – Marie Skłodowska-Curie Actions – Innovative Training Networks)



UNIVERSITÀ DEGLI STUDI
DI MILANO



Universiteit
Antwerpen



UNIVERSITY
OF ABERDEEN



LEIDS UNIVERSITAIR MEDISCH CENTRUM



Universitat
de Barcelona



BAYER



GPIP
EIPG



ingenus
Pharmaceuticals



Linkcare



Kemotech



PPD



biomax
biomax informatics ag



HistoGeneX



edqm
European Directorate for the Quality of Medicines & HealthCare



COUNCIL OF EUROPE
CONSEIL DE L'EUROPE



EAS



HORIZON 2020

This project has received funding from the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 675527

**HORIZON 2020 - Marie Skłodowska-Curie
ITN-European Joint Doctorate**



MOGLY
NET
LIVING SCIENCE TOGETHER

**MOGLYNET-PhD programme in
DRUG DISCOVERY AND
DEVELOPMENT**

Project website: www.moglynet.com

CONTACTS
Secretary@moglynet.com
Tel. +390250314471
Fax +390250314476



MOGLY
NET
LIVING SCIENCE TOGETHER

MOGLYNET

**PhD programme in
DRUG DISCOVERY AND
DEVELOPMENT
2015-2019**

Scholarship Programme
Promoting Institutional Cooperation
and Mobility for
12 early stage researchers ⁹

Mijn project: H2020-MSCA-ITN (3)

(Horizon2020 – Marie Skłodowska-Curie Actions – Innovative Training Networks)

12 PhD posities:

- Europees / niet-Europees
- man / vrouw

Samenwerking tussen 5 universiteiten

Onderzoek naar nieuwe therapeutische
doelwitten in atherosclerose

Samenwerking met niet-academische
partners

RESEARCH PROJECT

Atherosclerotic cardiovascular disease is the leading cause of death in the western world. Thanks to cholesterol-lowering drugs, the lifespan and wellbeing of patients have been improved.

Our multidisciplinary approach is focused on counteracting neovessel formation to prevent plaque rupture and its cardiovascular complications, thus leading to a more effective therapy for atherosclerosis.

Beneficiaries

- University of Milan (Pharmaceutical Sciences and Pharmacological and Biomolecular Sciences Departments), Italy – **Coordinating University**
- University of Aberdeen (Institute of Medical Sciences, School of Medicine, Medical Sciences and Nutrition), UK
- University of Antwerp (Laboratory of Physiopharmacology), Belgium
- University of Barcelona (Department of Biochemistry and Molecular Biology), Spain
- Leiden University Medical Center (Department of Surgery and Einthoven Laboratory for Experimental Vascular Medicine), The Netherlands

Partners and Associations

- Bayer HealthCare Manufacturing S.r.l., Italy
- Biomax Informatics AG, Germany
- HistoGeneX N.V., Belgium
- KemoTech Srl, Italy
- Linkcare Health Services, Spain
- Ingenus Pharmaceutical GmbH, Switzerland
- PPD Italy srl, Italy
- EIPG (European Industrial Pharmacists Group)
- EAS (European Atherosclerosis Society)
- EDQM (European Directorate for the Quality of Medicines)

Doctorate Centres

- University of Milan: Doctoral School of Pharmaceutical Sciences
- University of Aberdeen: Graduate School in Life Sciences and Medicine
- University of Antwerp: Antwerp Doctoral School
- University of Barcelona: Doctoral School of Biochemistry and Molecular Biology
- University of Leiden: Graduate School of Leiden University Medical Center

Research Objectives:

- Computational chemistry and synthesis
- Bioanalytics and biophysics
- *In vitro* and *In vivo* biological evaluation
- Imaging
- Metabolomic and Proteomic studies
- Oxidative stress studies

Mijn ervaring

- Werkdag
- Omgeving
- Aangenaam
 - Nieuwe cultuur
 - Internationaal onderzoek (summer schools, ...)
 - Reizen (congres, seminaries, presentaties, ...)
- Moeilijker
 - Taalbarrière
 - Cultuurverschillen

Bedankt voor jullie aandacht VRAGEN??

"Stubbornness can be a good thing. Do not let anyone tell you that you can not do something."



Valérie Smolders

Marie Curie PhD Research Fellow
Department of Biology and Biotechnology
University of Barcelona, Spain

Email: valerie.smolders@ub.edu



The project leading to this application has received funding from the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 675527